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Background: Two receptors that contain the so-called ‘death domain’ have been
described to date: tumor necrosis factor receptor 1 (TNFR1) and Fas/Apo-1
(CD95); both belong to the TNFR gene family. The death domain of TNFR1
mediates the activation of programmed cell death (apoptosis) and of the
transcription factor NF-kB, whereas the death domain of CD95 only appears to
activate apoptosis.
Results: We have identified an additional member of the TNFR family, which we
have named Apo-3. Apo-3 is a transmembrane protein of approximately 47 kDa
that has similarity to members of the TNFR family in its extracellular, cysteine-rich
domains. In addition, Apo-3 resembles TNFR1 and CD95 in that it contains a
cytoplasmic death domain. The Apo-3 gene mapped to human chromosome
1p36.3, and Apo-3 mRNA was detected in several human tissues, including
spleen, thymus, peripheral blood lymphocytes, small intestine and colon. Ectopic
expression of Apo-3 in HEK293 or HeLa cells induced marked apoptosis. CrmA,
a poxvirus inhibitor of Ced-3-like proteases which blocks death signaling by
TNFR1 and CD95, inhibited Apo-3-induced apoptosis. Ectopic expression of
Apo-3 also induced the activation of NF-kB. Apo-3 did not specifically bind to
the Apo-2 ligand, suggesting the existence of a distinct ligand for Apo-3.
Conclusions: These results identify Apo-3 as a third member of the TNFR family
that activates apoptosis, and suggest that Apo-3, TNFR1 and CD95 engage a
common apoptotic cell-death machinery. Apo-3 resembles TNFR1 because it
can stimulate NF-kB activity and regulate apoptosis. Apo-3 mRNA is expressed
in various tissues, consistent with the possibility that this receptor may regulate
multiple signaling functions.
Background
The mammalian tumor necrosis factor receptor (TNFR)
gene family encodes ten different cell-surface proteins
that interact with a corresponding TNF-related ligand
family [1,2]. The receptors share homology in their extra-
cellular domain (ECD), which contains 3–6 cysteine-rich
pseudo-repeats, but are generally not related in their cyto-
plasmic regions. Two TNFR family members, TNFR1
and Fas/Apo-1 (CD95), can activate apoptotic cell death
[3]. These two receptors have additional homology in their
intracellular domain (ICD), in an oligomerization interface
known as the death domain [4,5]. Death domains are also
found in several other metazoan proteins that regulate
apoptosis — namely, the Drosophila protein Reaper [6,7]
and the mammalian proteins FADD/MORT1 [8,9],
TRADD [10] and RIP [11]. Upon ligand binding and
receptor clustering, TNFR1 and CD95 recruit the
FADD/MORT1 protein into a death-inducing signaling
complex; CD95 binds to FADD/MORT1 directly [8,9],
whereas TNFR1 binds indirectly to FADD/MORT1 via
TRADD [12,13]. FADD/MORT1 in turn recruits the thiol
protease MACHa/FLICE into the death signaling
complex [14,15]. MACHa/FLICE appears to be the first
component in a cascade of apoptotic proteases related to
the product of the Caenorhabditis elegans gene Ced-3 and to
mammalian interleukin-1b-converting enzyme (ICE).
Upon activation by proteolytic cleavage, these proteases
execute essential aspects of the cell-death program [3]. In
addition to initiating apoptosis, activation of TRADD by
TNFR1 can lead to stimulation of the transcription factor
NF-kB [4] through the interaction between TRADD and
another cytoplasmic protein called TRAF2 [12,16]. NF-kB
resides in the cytoplasm in a latent form, and upon activa-
tion by various stimuli, it migrates to the nucleus and
induces the transcription of immune-response genes [17].
To search for new members of the TNFR family that may
regulate apoptosis, we screened the DNA databases for
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expressed sequence tags (ESTs) that had sequence simi-
larity to TNFR1 and CD95. We identified two sets of
ESTs; one set had some sequence similarity to the ICDs
of TNFR1 and CD95, and the other set had some similar-
ity to the ECDs of these proteins. Based on the ICD-
related ESTs, we isolated cDNAs from human fetal heart
and fetal lung libraries that encoded a transmembrane
protein that resembles members of the TNFR family. We
named this protein Apo-3. The ECD-related ESTs corre-
sponded to the amino-terminal region of Apo-3. In this
paper, we report the primary structure of Apo-3 and
provide evidence that this receptor plays a role in the
regulation of apoptosis and of NF-kB.
Results
Primary structure of Apo-3
We screened human fetal heart and lung cDNA libraries
using synthetic oligonucleotide probes based on ESTs
that showed homology to the ICDs of TNFR1 and CD95
(see Materials and methods). We isolated a cDNA clone
from fetal heart which contains a single open reading
frame with an apparent translational initiation site [18]
surrounding a methionine encoded by nucleotides 89–91,
and which ends with a stop codon at nucleotide positions
1339–1341 (Fig. 1a); a polyadenylation sequence is
present at the 3′ end. The predicted polypeptide precur-
sor is 417 amino-acids long and has a calculated molecular
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Figure 1
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(a) Nucleotide and predicted amino-acid sequence of human Apo-3. The
putative signal peptide and transmembrane domain are shown in blue,
the death-domain sequence is shown in green, and the potential N-linked
glycosylation sites are marked by asterisks. Also indicated is the alanine
residue (red) which was present in the fetal lung but not the fetal heart
cDNA clone. (b) Comparison of the ECD sequences of human Apo-3,
TNFR1 and CD95. Amino acids conserved in at least two sequences
are boxed in blue. Cysteines that form the framework of each cysteine-
rich domain in the crystal structure of TNFR1 [37] are boxed in red. (c)
Comparison of the death-domain sequences of human Apo-3, TNFR1,
CD95, FADD/MORT1, TRADD, RIP and Drosophila Reaper. Amino
acids conserved in at least three of the sequences are boxed in blue.
weight of approximately 45 kDa and a PI of 6.4. Hydropa-
thy analysis (data not shown) suggested the presence of a
signal sequence (amino acids 1–24), followed by an extra-
cellular region (amino acids 25–198), a transmembrane
domain (amino acids 199–224) and an intracellular region
(amino acids 225–417) (Fig. 1a). 
The cDNA sequence suggests that there are two potential
N-linked glycosylation sites at amino-acid positions 67
and 106. The ECD contains four cysteine-rich pseudo-
repeats which resemble the corresponding regions of
human TNFR1 (four repeats) and CD95 (three repeats)
(Fig. 1b), and of the other known TNFR family members
(data not shown). The ICD contains a sequence which
resembles the death domains found in the ICDs of
TNFR1 and CD95 and in other death signaling proteins,
such as human FADD/MORT1, TRADD, RIP and
Drosophila Reaper (Fig. 1c). Notably, four out of the six
amino-acid residues in the death domain of TNFR1 that
are essential for signaling (F345, R347, L351 and W378
[4]) are identical in Apo-3 (F350, R352, L356 and W382),
whereas the remaining two TNFR1 residues (E369 and
I408 [4]) are semiconserved in Apo-3 (D371 and L409)
(Fig. 1c). Both globally and in individual regions, Apo-3 is
related more closely to TNFR1 than to CD95; the respec-
tive percent identities are 29 % and 23 % overall, 28 % and
25 % in the ECD, 32 % and 18 % in the ICD, and 48 %
and 20 % in the death domain.
We isolated a related cDNA clone from fetal lung (data
not shown); this clone was identical to the fetal heart
clone, except that it was 172 bp shorter at the 5′ end, sug-
gesting that it was not full-length. In addition, the fetal
lung cDNA clone lacked the alanine residue at position
236, possibly due to differential mRNA splicing via two
consecutive splice-acceptor consensus sites (Fig. 1c).
Chromosomal localization of the Apo-3 gene
We investigated the chromosomal location of Apo-3 by
fluorescence in situ hybridization (FISH) to normal human
lymphocyte chromosomes. Direct hybridization using the
Apo-3 cDNA as a probe gave a poor signal-to-background
ratio (data not shown); however, the results suggested that
the gene was located on chromosome 1p36. To confirm
this finding, we screened a human genomic P1-derived
artificial chromosome (PAC) library using the Apo-3
probe. We identified a positive PAC clone, which mapped
by FISH to the short arm of chromosome 1, at position
1p36.3 (Fig. 2). A second Apo-3-positive PAC clone
mapped to the same position (data not shown).
Expression of Apo-3
We investigated Apo-3 mRNA expression in human
tissues by northern-blot hybridization to a 206 bp DNA
probe based on the 3′ untranslated region of the Apo-3
cDNA (Fig. 3a). A predominant mRNA transcript of
approximately 4 kb was detected in adult spleen, thymus
and peripheral blood lymphocytes; the Apo-3 mRNA was
less abundant in small intestine, colon, fetal lung and fetal
kidney. Additional transcripts of approximately 7 kb and
9 kb were seen mainly in fetal brain, lung and kidney, and
in adult spleen and ovary.
We expressed the Apo-3 protein by transiently transfecting
HEK293 cells with pRK5–Apo-3 (a pRK5-based plasmid
expressing Apo-3), and immunoprecipitated lysates of
metabolically labeled cells with a mouse antiserum raised
against an Apo-3–IgG fusion protein (see Materials and
methods). We observed a predominant radioactive band
with a relative molecular mass of approximately 47 kDa in
cells transfected with pRK5–Apo-3, but not in control cells
transfected with pRK5 (Fig. 3b, lanes 1,2); this band was
not present in control immunoprecipitates in which pre-
immune mouse serum was used (data not shown). Given
the potential glycosylation sites of Apo-3, the observed size
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Figure 2
Chromosomal localization of the Apo-3 gene. A human genomic clone
of Apo-3 was identified by screening a PAC library, and the PAC clone
was mapped by FISH to normal human lymphocyte chromosomes. The
chromosome 1 hybridization image, shown alongside a map of human
chromosome 1, is representative of 20 metaphase spreads. Positive
hybridization signals at 1p36.3 were noted in more than 95 % of the
cells. Signals were seen in both chromosome 1 homologues in more
than 90 % of the positive spreads.
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is consistent with the size of approximately 45 kDa pre-
dicted for the Apo-3 polypeptide precursor.
Ectopic expression of Apo-3 triggers apoptosis
Microscopic examination of Apo-3-transfected HEK293
cells 36 hours after transfection revealed that, compared
with pRK5-transfected controls, there was a substantial
loss of cell viability; membrane blebbing and loss of cell
volume were seen in many Apo-3-transfected cells (Fig.
4a,b), suggesting cell death by apoptosis [19]. To assess
this possibility directly, we analyzed the integrity of cellu-
lar DNA. Apo-3-transfected cells showed a marked
increase in DNA fragmentation as compared with controls
(Fig. 4j, lanes 1,2); the fragmented DNA migrated on
agarose gels as a series of bands with incrementally
increasing size, indicating internucleosomal DNA cleav-
age, a hallmark of programmed cell death [19]. As an addi-
tional assay for apoptosis, we measured a combination of
two parameters by fluorescence-activated cell sorting
(FACS) analysis — staining by the DNA-binding dye pro-
pidium iodide (PI), which indicates loss of plasma mem-
brane integrity, and binding of Annexin-V, which interacts
with phosphatidylserine on the surface of apoptotic cells
[20,21]. Double-negative cells are viable; Annexin-V-posi-
tive/PI-negative cells are in the early stages of apoptosis and
still maintain plasma membrane integrity; double-positive
cells are in the later stages of apoptosis, or are post-apop-
totic and have lost plasma membrane integrity; Annexin V-
negative/PI-positive cells are necrotic [20,21]. The transient
transfection efficiency of HEK293 cells was 60–70 % (data
not shown); in order to limit our analysis to those cells that
had taken up plasmid DNA, we co-transfected the cells
with a pRK5–CD4 expression vector; these cells were then
gated by staining for the CD4 marker. Transfection with
pRK5–Apo-3 resulted in a marked increase in the level of
double-positive cells, as compared with pRK5-transfected
controls (Fig. 4e,f). We also used FACS analysis to deter-
mine the effect of plasmid dose on apoptosis. Transfection
with plasmids encoding either Apo-3 or TNFR1 was asso-
ciated with a dose-dependent increase in apoptosis;
notably, the effect of Apo-3 was more pronounced than
that of TNFR1 (Fig. 4i). Taken together, these results
indicate that ectopic expression of Apo-3 in HEK293 cells
triggers apoptosis. Similar results were seen with HeLa
cells transfected with Apo-3 (data not shown), suggesting
that the apoptotic response to Apo-3 transfection is not
unique to the HEK293 cell line. 
CrmA inhibits induction of apoptosis by Apo-3
The apoptotic activity of the proteases ICE and
Yama/CPP32 can be inhibited effectively by the product
of the cowpox virus gene crmA [22,23]. CrmA inhibits
TNFR1- and CD95-induced cell death [24,25]. Co-trans-
fection of HEK293 cells with pRK5–CrmA and
pRK5–Apo-3 did not affect the expression levels of Apo-3
(Fig. 3b, lane 3); however, CrmA blocked Apo-3-associ-
ated apoptosis as assessed morphologically (Fig. 4c,d), by
FACS (Fig. 4g,h) and by DNA fragmentation (Fig. 4j
lanes 3,4). CrmA also inhibited apoptosis associated with
Apo-3-transfection in HeLa cells (data not shown). These
results suggest that the activity of proteases such as ICE
and Yama/CPP32 is required for Apo-3-induced apoptosis.
Apo-3 activates NF-kB
Given the similarity between the death-domain seq-
uences of Apo-3 and TNFR1, we investigated whether
Apo-3 activates NF-kB. Cells transfected with pRK5–-
Apo-3 showed a significant increase in NF-kB-specific
DNA-binding activity relative to pRK5-transfected con-
trols (Fig. 5); NF-kB was also activated in cells trans-
fected with pRK5–TNFR1. The levels of NF-kB activity
appeared higher in TNFR1-transfected cells than in
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Figure 3
(a) Expression of Apo-3 mRNA in human
tissues. Apo-3 mRNA expression was analyzed
by northern-blot hybridization to a 206 bp DNA
probe based on the 3′ untranslated region of
the Apo-3 cDNA. Lane 1, fetal brain; lane 2,
lung; lane 3, liver; lane 4, kidney; lane 5, adult
spleen; lane 6, thymus; lane 7, prostate; lane 8,
testis; lane 9, ovary; lane 10, small intestine;
lane 11, colon; lane 12, peripheral blood
lymphocytes. The sizes of molecular weight
standards (in kb) are shown on the left. 
(b) Ectopic expression of Apo-3 in HEK293
cells. Cells were transfected with 10mg
pRK5–Apo-3 plus 10 mg pRK5 (lane 1), 20 mg
pRK5 (lane 2), or 10 mg pRK5–Apo-3 plus
10 mg pRK5–CrmA (lane 3). After 24 h, cells
were metabolically labelled and extracts were
immunoprecipitated using a mouse antiserum
raised against an Apo-3–IgG fusion protein;
samples were subjected to SDS–PAGE and
phosphorimager analysis. The sizes of
molecular weight markers (in kDa) are shown
on the left.
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Apo-3-transfected cells (Fig. 5, compare lanes 3 and 4).
These results suggest that Apo-3 is linked to an NF-kB
activation pathway.
Apo-2 ligand does not bind to Apo-3
Recent studies have identified a new member of the TNF
cytokine family — called Apo-2L (for Apo-2 ligand [26,27]),
or TRAIL (for TNF-related apoptosis-inducing ligand [28])
— which resembles CD95 ligand and TNF in its apoptosis-
inducing activity. Because the receptor for Apo-2L is
unknown, we investigated whether Apo-2L interacts with
Apo-3 by testing the ability of 125I-labeled Apo-2L to bind
specifically to an Apo-3–IgG fusion protein (Fig. 6). The
125I-labeled Apo-2L did not bind specifically to Apo-3–IgG,
but bound specifically to a monoclonal anti-Apo-2L anti-
body. The 125I-labeled Apo-2L also failed to bind selec-
tively to the surface of HEK293 cells transfected with
pRK5–Apo-3 or with pRK5–Apo-3 plus pRK5–CrmA (data
not shown). These results suggest that Apo-3 is not a recep-
tor for Apo-2L.
Discussion
We have identified Apo-3 as an additional member of the
TNFR family. Apo-3 has four cysteine-rich domains in its
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Figure 4
Induction of apoptosis by ectopic expression of Apo-3 in HEK293 cells.
Apoptosis was assessed 36 h after transfection by morphological
analysis (a–d), by FACS (e–i), and by analysis of DNA fragmentation (j).
For morphological analysis, cells were transfected with 10 mg pRK5 (a),
5 mg pRK5 plus 5 mg pRK5–Apo-3 (b), 5 mg pRK5 plus 5 mg
pRK5–CrmA (c), or 5 mg pRK5–Apo-3 plus 5 mg pRK5–CrmA (d), and
photographed at 400× magnification by Hoffmann-based light
microscopy. For FACS analysis, cells were transfected with 3 mg
pRK–CD4 as a marker for plasmid uptake, together with 10 mg pRK5
(e), 5 mg pRK5 plus 5 mg pRK5–Apo-3 (f), 5 mg pRK5 plus 5 mg
pRK5–CrmA (g), or 5 mg pRK5–Apo-3 plus 5 mg pRK5–CrmA (h). The
cells were gated by staining with a phycoerythrin-conjugated anti-CD4
antibody before FACS analysis of staining by Annexin-V–FITC and PI.
The percent apoptosis in (e–h), respectively, was 37 %, 66 %, 36 % and
26 %. In (i), cells were transfected with the indicated amount of
pRK5–Apo-3 or pRK5–TNFR1, together with pRK–CD4 and the
appropriate amount of pRK5 to adjust the total amount of plasmid to
20 mg, and analyzed by FACS as above. For the DNA fragmentation
assay (j), cells were transfected with 10 mg pRK5 (lane 1), 5 mg pRK5
plus 5 mg pRK5-Apo-3 (lane 2), 5 mg pRK5 plus 5 mg pRK5–CrmA
(lane 3), or 5 mg pRK5–Apo-3 plus 5 mg pRK5–CrmA (lane 4). The DNA
was extracted, radiolabeled by 32P in a terminal transferase reaction, and
subjected to agarose gel electrophoresis and phosphorimager analysis.
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Figure 5
Activation of NF-kB by ectopic expression of Apo-3 in HEK293 cells. Cells
were transfected with 10 mg pRK5 (lanes 1,4,7), 10 mg pRK5–Apo-3
(lanes 2,5,8), or 10 mg pRK5–TNFR1 (lanes 3,6,9). Nuclear extracts were
prepared 36 h later and reacted with a non-specific 32P-labeled
oligonucleotide probe (lanes 1–3), or with a 32P-labeled, NF-kB-specific
probe, alone (lanes 4–6), or together with a 50-fold excess of unlabelled
oligonucleotide of the same sequence (lanes 7–9). The reactions were
subjected to electrophoretic mobility-shift assay and the gel was analyzed
by phosphorimager analysis. The band at the bottom of the gel in all lanes
is the free labeled probe. The two other bands seen in lanes 1–3 represent
non-specific interactions, as does the band common to lanes 1–3 and
4–6. The top band in lanes 4–6 represents the labelled NF-kB-specific
probe, whose migration is delayed by specific interaction with activated
NF-kB protein in the nuclear extracts.
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extracellular region. In addition, Apo-3 has a cytoplasmic
death domain that is related to the death domains of
TNFR1 and CD95, as well as to the death domains of intra-
cellular regulators of apoptosis such as FADD/MORT1,
TRADD, RIP and Reaper. Apo-3 mRNA is expressed both
in lymphoid and in non-lymphoid human tissues, suggest-
ing that it may regulate signaling functions in multiple
types of cells. Apo-3 does not appear to interact with Apo-
2L, suggesting the existence of a separate Apo-3 ligand and
a distinct Apo-2 receptor.
The Apo-3 gene mapped to position 1p36.3 on human
chromosome 1. Recent work shows that a genomic region
which is deleted in certain human neuroblastomas maps
between 1p36.2–1p36.3, suggesting the presence of a
tumor suppressor gene at this locus [29]. Four additional
TNFR gene family members — TNFR2, CD30, 4-1BB
and OX40 — reside in 1p36 [2], but are outside the
deleted region [29].
Ectopic expression of Apo-3 resulted in apoptosis, as
judged by morphological and biochemical criteria. Hence,
one biological role of Apo-3 may be to trigger a cell-death
program upon binding of its cognate ligand. CrmA inhib-
ited Apo-3-induced apoptosis, suggesting that proteases
such as ICE and/or Yama/CPP32 may be involved in
executing the cell-death signal emanating from Apo-3.
Thus, Apo-3, TNFR1 and CD95 appear to activate a
common apoptotic cell-death machinery. Transfection
with a plasmid encoding Apo-3 also resulted in the activa-
tion of NF-kB, indicating that, like TNFR1, Apo-3 is
capable of regulating not only cell death, but also tran-
scription of inflammatory response genes. Therefore, the
eventual outcome of Apo-3 activation may be determined
by the cellular context in which it is triggered. This possi-
bility is consistent with the expression of Apo-3 mRNA in
a variety of tissues. 
Our conclusion that Apo-3 regulates apoptosis and NF-kB
is based on the premise that overexpression of this receptor
mimics ligand-dependent activation. This notion is sup-
ported by the previous observation that ectopic expression
of TNFR1 leads to spontaneous self-association of the
receptor and to activation of apoptosis and NF-kB-depen-
dent gene expression [30]. In addition, ligand-independent
dimerization of CD95, induced intracellularly by a chemi-
cal dimerizing agent, is sufficient to trigger apoptosis [31].
Self-association appears also to be an activation mechanism
of other death-domain-containing proteins, such as
TRADD, FADD, RIP and Reaper, whose overexpression
leads to activation of apoptosis [8–11,32].
Conclusions
Apo-3 is a novel member of the TNFR family. The Apo-3
gene is encoded on human chromosome 1, and its mRNA
is expressed in multiple tissues. Like TNFR1 and CD95,
Apo-3 contains a cytoplasmic death domain, and appears
to trigger a similar apoptotic cell-death pathway which is
inhibited by CrmA. In addition, Apo-3 appears to be
capable of activating the transcription factor NF-kB, sug-
gesting that, like TNFR1, this receptor may regulate dis-
tinct signaling pathways in different cellular contexts.
Future studies should aim at isolating a specific ligand for
Apo-3 to help elucidate the physiological role of this
receptor.
Materials and methods
Isolation of Apo-3 cDNAs
Human fetal heart and human fetal lung lgt10 bacteriophage cDNA
libraries (Clontech) were screened by hybridization with synthetic
oligonucleotide probes based on a set of ESTs represented by
GenBank site W71984, which showed some degree of homology
to the ICDs of human TNFR1 and CD95. The oligonucleotide
probes were: 5′–GGCGCTCTGGTGGCCCTTGCAGAAGCC; and
5′–TTCGGCCGAGAAGTTGAGAAATGTC. Another EST set (for
example, GenBank site H41522), which showed some degree of
homology to the ECDs of human TNFR1 and CD95, corresponds to
the ECD of Apo-3. One positive clone each from the fetal heart
(FH20A.57) and the fetal lung (FL8A.53) libraries was isolated and
sequenced in its entirety.
Accession number
The GenBank accession number for the Apo-3 cDNA is U74611.
Northern-blot analysis
Expression of Apo-3 mRNA in human tissues was examined by northern-
blot analysis. Human fetal RNA blot MTN (Clontech) and human adult
RNA blot MTN-II (Clontech) were hybridized to a 206 bp 32P-labeled
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Figure 6
Lack of specific interaction between Apo-3–IgG and Apo-2 ligand. The
binding of 1 nM 125I-labeled Apo-2L (125I–Apo-2L) to a monoclonal
anti-Apo-2L antibody or to an Apo-3–IgG fusion protein was analyzed
in the absence (white bars) or presence (grey bars) of 100 nM
unlabeled Apo-2L. The data are means ± standard errors (n = 4).
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DNA probe based on the 3′ untranslated region of Apo-3. The probe was
generated by PCR using the oligonucleotides that were used to screen
the fetal heart and lung libraries.
FISH mapping
Mapping was performed by FISH [33] to normal human lymphocyte
chromosomes counterstained with PI and DAPI. Biotinylated Apo-3
probes were detected with avidin–FITC. The Apo-3 cDNA probe was
also used to identify clones in a genomic PAC library that contained the
Apo-3 gene, and the PACs were used as confirmatory probes in FISH.
The regional assignment of the genomic probe was determined by ana-
lyzing 20 metaphase spreads.
Expression of Apo-3 
pRK5-based mammalian expression plasmids carrying clone
FH20A.57 (pRK5–Apo-3), TNFR1 (pRK5–TNFR1), or CD4
(pRK5–CD4) were constructed and transiently transfected into
HEK293 cells by calcium phosphate precipitation; HeLa cells were
transfected by electroporation. The total amount of plasmid DNA was
kept constant for each set of transfections.
Analysis of apoptosis 
Cells were analyzed for apoptosis 36 h after transfection. Apoptosis
was assessed morphologically, or quantitated by FACS analysis of
cells stained with FITC-conjugated Annexin V (Brand Applications),
which binds to exposed phosphatidylserine on the surface of apop-
totic cells, and by staining with PI, which penetrates cells that have
lost membrane integrity [20,21]. DNA fragmentation was analyzed by
extracting DNA from cells, and 32P-labelling the 3′ ends with terminal
transferase using an Apoptotic DNA Laddering kit (Trevigen);
samples were separated by 1.5 % agarose gel electrophoresis, as
described [26].
Radioimmunoprecipitation
Transfected cells (5 × 105 per lane) were metabolically labeled by
adding 50 mCi 35S-labelled methionine and 35S-labelled cysteine to the
growth media 24 h after transfection. After a 6 h incubation, the cells
were washed several times, lyzed, and subjected to immunoprecipita-
tion using anti-Apo-3 antiserum as described [34]. The anti-Apo-3 anti-
serum was raised in mice against a fusion protein comprised of the
Apo-3 ECD linked to the human IgG1 hinge and Fc, which was con-
structed and purified essentially as described [35]. Pre-immune serum
was derived from the same mice before immunization.
NF-kB activation
Cells were harvested 36 h after transfection, nuclear extracts were pre-
pared, and 1 mg of nuclear protein was incubated with a duplex, 32P-
labeled NF-kB-specific synthetic oligonucleotide probe (top strand
sequence: 5′–ATCAGGGACTTTCCGCTGGGGACTTTCCG), alone
or together with a 50-fold excess of unlabelled probe, or with a non-
specific duplex 32P-labelled synthetic oligonucleotide (top strand
sequence: 5′–AGGATGGGAAGTGTGTGATATATCCTTGAT). DNA
binding was analyzed by electrophoretic mobility-shift assay, as
described [12,34,36].
Apo-2L binding assay
Soluble human Apo-2L [26] was radio-iodinated using Enzymobeads
(BioRad) to a specific activity of 67 mCi mg–1. The biological activity  of
the iodinated protein was equivalent to that of non-iodinated Apo-2L,
as measured by apoptosis induction in the human 9D cell line [26].
Microtiter wells were coated with goat anti-mouse Fc or anti-human Fc
antibody and blocked with bovine serum albumin. A neutralizing mono-
clonal mouse anti-Apo-2L antibody, or Apo-3–IgG fusion protein
(5 mg ml–1) were bound to the anti-mouse or anti-human Fc antibodies,
respectively; incubations were carried out using 125I-labelled Apo-2L
(1 nM) for 2 h at 24 °C. Non-specific binding was determined in the
presence of 100 nM unlabeled Apo-2L.
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